Pathologic Complete Response to Neoadjuvant Nivolumab/Ipilimumab in a Patient with Metastatic Renal Cell Carcinoma

Nivolumab plus ipilimumab represents an effective combination of checkpoint inhibitors that can lead to a durable response with minimal toxicity in patients with metastatic renal cell carcinoma (mRCC). We present a case of a pathologic complete response to neoadjuvant nivolumab plus ipilimumab in a...

詳細記述

保存先:
書誌詳細
出版年:Case Rep Urol
主要な著者: Peak, Taylor C., Fenu, Elena M., Rothberg, Michael B., Thomas, Christopher Y., Davis, Ronald L., Levine, Edward A.
フォーマット: Artigo
言語:Inglês
出版事項: Hindawi 2020
主題:
Case Report
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC7652618/
https://ncbi.nlm.nih.gov/pubmed/33204569
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2020/8846135
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料